A study to find out whether Odronextamab is safe and well tolerated and how effective it is compared to Rituximab in combination with different types of chemotherapy in participants with follicular lymphoma
Résumé de l'étude
The study investigates the drug Odronextamab, referred to as the investigational product. The study focuses on patients with previously untreated follicular lymphoma (a type of non-Hodgkin lymphoma, NHL). The study is divided into Part 1 and Part 2. The aim of Part 1 of the study is to determine how safe and well tolerated the investigational product is. The aim of Part 2 of the study is to investigate the effect of Odronextamab compared to Rituximab and chemotherapy (the current standard treatment for non-Hodgkin lymphoma). Several research questions are explored in the study, including: • What side effects can the investigational product cause? • How much of the investigational product is present in the blood at different times? • Does the body produce antibodies against the investigational product (which could make the drug less effective or lead to side effects)? • The effects of the investigational product on the quality of life and daily functioning of the patients.
(BASEC)
Intervention étudiée
Odronextamab is a monoclonal antibody described as bispecific because it can individually recognize and bind to 2 cell proteins (CD20 and CD3). Proteins are part of every cell in the body, working like small machines to ensure the function of the cell. CD20 is a protein found on the surface of both normal B cells and B cells that form certain cancers, such as follicular lymphoma. CD3 is a protein found on the surface of T cells. T cells and normal B cells are types of white blood cells in the body and are part of the immune system that fights infections. Odronextamab is intended to help T cells find and kill B cells, including cancer cells in follicular lymphoma.
(BASEC)
Maladie en cours d'investigation
Participants must be at least 18 years old and have untreated follicular lymphoma.
(BASEC)
– Participants must be at least 18 years old – have follicular lymphoma – Participants have not received prior treatment for follicular lymphoma (BASEC)
Critères d'exclusion
– Participants with follicular lymphoma that has occurred in the brain or has spread to the brain (known as leptomeningeal involvement) or with certain cancers such as central nervous system lymphoma, high-grade follicular lymphoma (also referred to as type 3b) or with diffuse large B-cell lymphoma – Participants with uncontrolled hepatitis B, uncontrolled hepatitis C, or uncontrolled HIV infections (human immunodeficiency virus). If your blood tests positive for cytomegalovirus (CMV), you must receive treatment for that and show a negative test result on two occasions at least one week apart before you can be included in the study. – Pre-existing conditions of the brain and spinal cord, as described in the study protocol (BASEC)
Lieu de l’étude
Bâle, Berne, St-Gall, Winterthur, Zurich, Autre
(BASEC)
Baden
(BASEC)
Sponsor
ICON Clinical Research GmbH Switzerland
(BASEC)
Contact pour plus d'informations sur l'étude
Personne de contact en Suisse
Clinical Trials Administrator
+1 844-734-6643
clinicaltrials@clutterregeneron.comRegeneron Pharmaceuticals, Inc.
(BASEC)
Informations scientifiques
non disponible
Nom du comité d'éthique approbateur (pour les études multicentriques, uniquement le comité principal)
Ethikkommission Nordwest- und Zentralschweiz EKNZ
(BASEC)
Date d'approbation du comité d'éthique
29.11.2023
(BASEC)
Identifiant de l'essai ICTRP
non disponible
Titre officiel (approuvé par le comité d'éthique)
Eine offene, randomisierte Phase-III-Studie zum Vergleich der Wirksamkeit und Sicherheit von Odronextamab (REGN1979), einem bispezifischen Anti-CD20 x Anti-CD3-Antikörper, gegenüber der Wahl des Prüfarztes bei zuvor unbehandelten Teilnehmern mit follikulärem Lymphom (OLYMPIA-1) (BASEC)
Titre académique
non disponible
Titre public
non disponible
Maladie en cours d'investigation
non disponible
Intervention étudiée
non disponible
Type d'essai
non disponible
Plan de l'étude
non disponible
Critères d'inclusion/exclusion
non disponible
non disponible
Critères d'évaluation principaux et secondaires
non disponible
non disponible
Date d'enregistrement
non disponible
Inclusion du premier participant
non disponible
Sponsors secondaires
non disponible
Contacts supplémentaires
non disponible
ID secondaires
non disponible
Résultats-Données individuelles des participants
non disponible
Informations complémentaires sur l'essai
non disponible
Résultats de l'essai
Résumé des résultats
non disponible
Lien vers les résultats dans le registre primaire
non disponible